126 related articles for article (PubMed ID: 35940259)
1. Target cell line characterization reveals changes in expression of a key antigen that impacts T cell dependent cellular cytotoxicity assay performance.
Matthies K; Crouse-Zeineddini J
J Immunol Methods; 2022 Oct; 509():113326. PubMed ID: 35940259
[TBL] [Abstract][Full Text] [Related]
2. Characterization of bispecific T-cell Engager (BiTE) antibodies with a high-capacity T-cell dependent cellular cytotoxicity (TDCC) assay.
Nazarian AA; Archibeque IL; Nguyen YH; Wang P; Sinclair AM; Powers DA
J Biomol Screen; 2015 Apr; 20(4):519-27. PubMed ID: 25477202
[TBL] [Abstract][Full Text] [Related]
3. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110.
Deisting W; Raum T; Kufer P; Baeuerle PA; Münz M
PLoS One; 2015; 10(10):e0141669. PubMed ID: 26510188
[TBL] [Abstract][Full Text] [Related]
4. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
5. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
Laszlo GS; Gudgeon CJ; Harrington KH; Dell'Aringa J; Newhall KJ; Means GD; Sinclair AM; Kischel R; Frankel SR; Walter RB
Blood; 2014 Jan; 123(4):554-61. PubMed ID: 24311721
[TBL] [Abstract][Full Text] [Related]
6. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.
Giffin MJ; Cooke K; Lobenhofer EK; Estrada J; Zhan J; Deegen P; Thomas M; Murawsky CM; Werner J; Liu S; Lee F; Homann O; Friedrich M; Pearson JT; Raum T; Yang Y; Caenepeel S; Stevens J; Beltran PJ; Canon J; Coxon A; Bailis JM; Hughes PE
Clin Cancer Res; 2021 Mar; 27(5):1526-1537. PubMed ID: 33203642
[TBL] [Abstract][Full Text] [Related]
7. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
8. Characterization of an Anti-CD70 Half-Life Extended Bispecific T-Cell Engager (HLE-BiTE) and Associated On-Target Toxicity in Cynomolgus Monkeys.
Harper T; Sharma A; Kaliyaperumal S; Fajardo F; Hsu K; Liu L; Davies R; Wei YL; Zhan J; Estrada J; Kvesic M; Nahrwold L; Deisting W; Panzer M; Cooke K; Lebrec H; Nolan-Stevaux O
Toxicol Sci; 2022 Aug; 189(1):32-50. PubMed ID: 35583313
[TBL] [Abstract][Full Text] [Related]
9. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
10. A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.
Lund ME; Howard CB; Thurecht KJ; Campbell DH; Mahler SM; Walsh BJ
BMC Cancer; 2020 Dec; 20(1):1214. PubMed ID: 33302918
[TBL] [Abstract][Full Text] [Related]
11. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule.
Pham E; Friedrich M; Aeffner F; Lutteropp M; Mariano NF; Deegen P; Dahlhoff C; Vogel F; Bluemel C; Harrold JM; Brandl C; Grinberg N; Rattel B; Coxon A; Bailis JM
Mol Cancer Ther; 2021 Oct; 20(10):1977-1987. PubMed ID: 34376583
[TBL] [Abstract][Full Text] [Related]
13. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
English DP; Bellone S; Schwab CL; Roque DM; Lopez S; Bortolomai I; Cocco E; Bonazzoli E; Chatterjee S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Cancer; 2015 Feb; 121(3):403-12. PubMed ID: 25251053
[TBL] [Abstract][Full Text] [Related]
14.
Moek KL; Waaijer SJH; Kok IC; Suurs FV; Brouwers AH; Menke-van der Houven van Oordt CW; Wind TT; Gietema JA; Schröder CP; Mahesh SVK; Jorritsma-Smit A; Lub-de Hooge MN; Fehrmann RSN; de Groot DJA; de Vries EGE
Clin Cancer Res; 2019 Jun; 25(12):3517-3527. PubMed ID: 30745297
[TBL] [Abstract][Full Text] [Related]
15. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys.
Goldstein RL; Goyos A; Li CM; Deegen P; Bogner P; Sternjak A; Thomas O; Klinger M; Wahl J; Friedrich M; Rattel B; Lamas E; Min X; Sudom A; Farshbaf M; Coxon A; Balazs M; Arvedson T
Blood Adv; 2020 Sep; 4(17):4180-4194. PubMed ID: 32886754
[TBL] [Abstract][Full Text] [Related]
16. Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
Suurs FV; Lorenczewski G; Bailis JM; Stienen S; Friedrich M; Lee F; van der Vegt B; de Vries EGE; de Groot DA; Lub-de Hooge MN
J Nucl Med; 2021 Apr; 62(12):1797-804. PubMed ID: 33931466
[TBL] [Abstract][Full Text] [Related]
17. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
[TBL] [Abstract][Full Text] [Related]
18. Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells.
Torisu-Itakura H; Schoellhammer HF; Sim MS; Irie RF; Hausmann S; Raum T; Baeuerle PA; Morton DL
J Immunother; 2011 Oct; 34(8):597-605. PubMed ID: 21904216
[TBL] [Abstract][Full Text] [Related]
19. The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer.
Deegen P; Thomas O; Nolan-Stevaux O; Li S; Wahl J; Bogner P; Aeffner F; Friedrich M; Liao MZ; Matthes K; Rau D; Rattel B; Raum T; Kufer P; Coxon A; Bailis JM
Clin Cancer Res; 2021 May; 27(10):2928-2937. PubMed ID: 33504551
[TBL] [Abstract][Full Text] [Related]
20. Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect
Zhong L; Shi W; Gan L; Liu X; Huo Y; Wu P; Zhang Z; Wu T; Peng H; Huang Y; Zhao Y; Yuan Y; Deng Z; Tang H
Theranostics; 2021; 11(13):6393-6406. PubMed ID: 33995664
[No Abstract] [Full Text] [Related]
[Next] [New Search]